“…Whilst demonstrating discrete anti-myeloma effects, many of these agents have also shown potential anti-tumour immune effects [13][14][15][16]. The IMiDs (thalidomide, lenalidomide and pomalidomide) in particular have not only shown great promise in the clinic as tumouricidal agents but also have immune skewing functions which may contribute to their anti-myeloma effect.…”